Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Beats on EPS, Stock Down 2.97%

Ligand Pharmaceuticals reported a strong EPS figure that significantly exceeded expectations, showcasing its ability to generate profits. However, the stock fell by nearly 3% in reaction to the earnings report, which may suggest investor concerns about the lack of revenue details and future guidance. Without clear direction from management, investors may remain cautious moving forward.